Navigation Links
Pfizer Enters Into Agreement to Acquire 40 Percent Stake in Teuto in Brazil
Date:10/20/2010

NEW YORK, Oct. 20 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that it is entering into a partnership with Laboratorio Teuto Brasileiro S.A., a leading company in the Brazilian generics industry, to develop and commercialize generic medicines.  Pfizer will acquire a 40 percent stake in Teuto and the companies will also enter into a series of commercial agreements.  The partnership will enhance Pfizer's position in Brazil, a key emerging market, by providing access to Teuto's broad portfolio of approximately 250 products in more than 400 presentations.  Through this partnership, Pfizer will have access to significant distribution networks in rural and suburban areas in Brazil and the opportunity to register and commercialize Teuto's products in various markets outside Brazil.  In addition, Pfizer will have two representatives on Teuto's board of directors.

(Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO)

Under the terms of the agreement, Pfizer will make an upfront payment of R$400 million (approximately US$240 million) and Teuto will be eligible to receive a performance-based milestone payment.  Pfizer has an option to acquire the remaining 60 percent of Teuto's shares beginning in 2014.  Teuto's shareholders have an option to sell their 60 percent stake to Pfizer beginning in 2015.

Pfizer will have the opportunity to register and commercialize Teuto products in Brazil and various markets outside of the country under its own brands, including branded and unbranded generic medicines, covering a broad range of therapeutic areas, such as pain and inflammation, cardiovascular, anti-infectives, central nervous system and respiratory, among others.  Teuto will gain access to select Pfizer products for distribution across its exten
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. MannKind Addresses Pfizers Announcement Regarding Exubera
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
11. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... HILL, N.C. , July 31, 2015 /PRNewswire/ ... product success in the biopharmaceutical market. Patients are ... process of selecting and switching therapies. This shift ... is pushing marketers, efforts toward patient-focused marketing. ... patient engagement, marketers have learned it,s important to ...
(Date:7/31/2015)... HILL, N.C. , July 31, 2015  In ... of customers who are increasingly mobile, increasingly connected, and ... a growing variety of customer interaction channels and tools ... technology, including social media. According to ... the over the counter (OTC) segment in a call ...
(Date:7/31/2015)...  Seeger Weiss LLP is reporting that on July 13, ... to C.R. Bard, the manufacturer of Inferior vena cava ... violations the agency found at two of Bard,s facilities. Bard ... cited them during Inspectional Observations that occurred on November 18, ... AZ , location and on October 6, 2014, through ...
Breaking Medicine Technology:Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
... of its Proprietary Technology to Provide Accurate, Fully ... 34th Annual ISCE MeetingSANTA CLARA, Calif., March 31 ... cardiac diagnostic and services company, today announced that ... abstracts and discuss applications for its proprietary technology ...
... published in the Journal of Medicinal Food, ... (1/3 ounce) of "Sun Chlorella A" daily resulted in ... and fasting blood glucose levels.For a 12-week period, 34 ... each morning and evening. Seventeen subjects were healthy; ...
Cached Medicine Technology:NewCardio Leadership to Present Two Abstracts at ISCE Conference 2NewCardio Leadership to Present Two Abstracts at ISCE Conference 3NewCardio Leadership to Present Two Abstracts at ISCE Conference 4First Human Study to Show 'Sun Chlorella A' Supports Heart Health 2
(Date:7/31/2015)... ... July 31, 2015 , ... Jacksonville-based drug ... new True North Conference Center. The medical community, social workers, law enforcement, and ... be more aligned in the effort to better understand and combat sex trafficking. ...
(Date:7/31/2015)... PA (PRWEB) , ... July 31, 2015 , ... M3 ... is excited to launch three new Board Exam Courses. , The additions of ... Doc Board Exam Prep from MDLinx makes preparing for the exam easy and painless. ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to an article published July ... they could reach a consensus on the steps that need to be taken to ... reached 90 percent consensus on a series of steps that each surgeon must complete ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... readers and potential patients alike on various plastic surgery procedures including, but not ... include such popular dermatology procedures like Botox and fillers. , Staying up ...
(Date:7/31/2015)... ... 31, 2015 , ... Transfinder, a software company based in Schenectady, N.Y., achieved ... percent year-over-year for the first six months ended June 30, 2015 compared with the ... beat last year’s record-revenue mark of $10.4 million. , “We know what our customers ...
Breaking Medicine News(10 mins):Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2Health News:Transfinder Closes First Half of 2015 with Record Revenue 2
... Babies 2008 Official Shoes are Now On Sale, WHITE ... up with Famous Footwear(TM) and Dr. Scholl,s(R) to,introduce the 2008 ... consecutive year, Famous Footwear and Dr. Scholl,s are,raising funds for ... Scholl,s specially designed one men,s and two women,s athletic shoes ...
... Dialysis Corporation,of America (Nasdaq: DCAI ) announced today ... year financial results on March 13, 2008, after the,close ... conference calls,in conjunction with its quarterly earnings releases, beginning ... following morning, March 14,2008 at 10:00 AM EDT., ...
... TOKYO, JAPAN & PRINCETON, NEW JERSEY, FEBRUARY 29 -- ... BMY) announced today that the U.S. Food and Drug ... ABILIFY (aripiprazole) for the acute treatment of manic and ... without psychotic features in pediatric patients (10 to 17 ...
... Mojave Desert, Calif., has found that soils under desert pavement ... salt, close to the surface. Vulnerable to erosion by rain ... source of nitrate could contaminate surface and groundwaters, posing an ... March issue of Geology . , Desert pavement is ...
... Japanese Society of Hematology announce a new partnership to ... is available (back to 1997) on Springers online ... a year and was previously published by Carden Jennings. ... is the official journal of the Japanese Society of ...
... of Atlanta, one,of the country,s leading pediatric healthcare ... of pediatric research in Georgia. The,Children,s Board of ... pediatric research., "Annually, income generated from this ... James E. Tally, Ph.D., president and,CEO of Children,s, ...
Cached Medicine News:Health News:Famous Footwear, Dr. Scholl's Step Up to Support March for Babies 2008 2Health News:Dialysis Corporation of America Announces Fiscal Year 2007 Earnings Release Date 2Health News:ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old 2Health News:ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old 3Health News:ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old 4Health News:Large source of nitrate, a potential water contaminant, found in near-surface desert soils 2Health News:Large source of nitrate, a potential water contaminant, found in near-surface desert soils 3Health News:Springer to publish International Journal of Hematology 2Health News:Children's Healthcare of Atlanta Announces Major Investment in Pediatric Research as Part of 10-Year Vision 2Health News:Children's Healthcare of Atlanta Announces Major Investment in Pediatric Research as Part of 10-Year Vision 3
... Whether for bypass grafting or creation of ... placed tissue tunnel is of the utmost ... is the answer for those seeking a ... configuration minimizes the risk of twisting or ...
... Cardiovascular Patch utilizes advanced fluoropolymer ... around penetrating suture and decrease ... much as 88 percent. This ... retention, multi-directional strength and low ...
... Vascular Grafts have met the challenges ... Recognized for exceptional performance and quality, ... renowned surgeons worldwide. These grafts require ... spread of infection, and ensure utmost ...
... GORE-TEX Stretch Vascular Grafts have met ... vascular procedures. Recognized for exceptional performance ... endorsement of renowned surgeons worldwide. These ... and the spread of infection, and ...
Medicine Products: